Short Interest in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Declines By 65.4%

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 5,400 shares, a drop of 65.4% from the August 15th total of 15,600 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 14,200 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily trading volume, of 14,200 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the company’s stock are short sold.

ALPS Medical Breakthroughs ETF Stock Performance

ALPS Medical Breakthroughs ETF stock opened at $36.81 on Friday. The business has a fifty day moving average of $33.86 and a two-hundred day moving average of $30.72. ALPS Medical Breakthroughs ETF has a twelve month low of $22.33 and a twelve month high of $42.73.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

A number of hedge funds have recently made changes to their positions in the stock. Strategic Financial Services Inc. grew its stake in ALPS Medical Breakthroughs ETF by 12.7% in the first quarter. Strategic Financial Services Inc. now owns 19,225 shares of the company’s stock valued at $548,000 after purchasing an additional 2,163 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of ALPS Medical Breakthroughs ETF in the 2nd quarter valued at about $82,000. Rossby Financial LCC bought a new stake in shares of ALPS Medical Breakthroughs ETF in the 1st quarter valued at about $147,000. Ally Invest Advisors Inc. purchased a new position in shares of ALPS Medical Breakthroughs ETF in the 2nd quarter worth approximately $200,000. Finally, Moran Wealth Management LLC bought a new position in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter worth approximately $300,000.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.